WO2022010864A1 - Dispositif d'administration de médicament pour l'administration de propionate de clobétasol - Google Patents

Dispositif d'administration de médicament pour l'administration de propionate de clobétasol Download PDF

Info

Publication number
WO2022010864A1
WO2022010864A1 PCT/US2021/040467 US2021040467W WO2022010864A1 WO 2022010864 A1 WO2022010864 A1 WO 2022010864A1 US 2021040467 W US2021040467 W US 2021040467W WO 2022010864 A1 WO2022010864 A1 WO 2022010864A1
Authority
WO
WIPO (PCT)
Prior art keywords
delivery device
drug delivery
reservoir
clobetasol propionate
substrate
Prior art date
Application number
PCT/US2021/040467
Other languages
English (en)
Inventor
Kraig D. KROELLS
Philip Stankard
Matthew Tyler Zabel
Timothy A. Peterson
Keith DAHMEN
Original Assignee
Kindeva Drug Delivery L.P.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kindeva Drug Delivery L.P. filed Critical Kindeva Drug Delivery L.P.
Publication of WO2022010864A1 publication Critical patent/WO2022010864A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone

Definitions

  • the drug delivery device includes a substrate that includes a film cured under an atmospheric-pressure nitrogen dielectric barrier discharge, a reservoir disposed on at least a portion of the substrate, and a release liner disposed on at least a portion of the reservoir.
  • the reservoir generally includes an adhesive composition and clobetasol propionate.
  • the reservoir includes clobetasol propionate at a concentration of 0.005 wt% to 1.0 wt%.
  • the film includes provides an occlusive backing.
  • the occlusive backing can include polyurethane, polyethylene, polyethylene terephthalate (PET), or a PET polyolefin laminate.
  • the adhesive composition can include a silicone adhesive composition.
  • the silicone adhesive composition includes a blend of silicate resin and silicone polymer.
  • the silicone adhesive composition includes two or more silicone polymers. In some of these embodiments, at least one silicone polymer includes trimethylsilyl end groups.
  • the reservoir can further include an antioxidant.
  • the antioxidant can include propyl gallate.
  • this disclosure described a drug delivery device that generally includes a substrate, a reservoir disposed on at least a portion of the substrate, and a release liner disposed on at least a portion of the reservoir.
  • the reservoir includes clobetasol propionate and an adhesive composition that includes a blend of silicate resin and silicone polymer provided in a silicate resin: silicone polymer ratio of from 57:43 to 59:41.
  • the reservoir includes clobetasol propionate at a concentration of 0.005 wt% to 1.0 wt%.
  • the film can provide an occlusive backing.
  • the occlusive backing can include polyurethane, polyethylene, polyethylene terephthalate (PET), or a PET polyolefin laminate.
  • the silicate resimsilicone polymer ratio is from 58:42 to 59:41.
  • the reservoir can further include an antioxidant.
  • the antioxidant can include propyl gallate.
  • this disclosure describes a drug delivery device that generally includes a substrate, a reservoir disposed on at least a portion of the substrate, and a release liner disposed on at least a portion of the reservoir.
  • the reservoir includes clobetasol propionate and an adhesive composition comprising at least one silicone polymer having trimethyl silyl end groups.
  • the reservoir includes clobetasol propionate at a concentration of 0.005 wt% to 1.0 wt%.
  • the film can provide an occlusive backing.
  • the occlusive backing can include polyurethane, polyethylene, polyethylene terephthalate (PET), or a PET polyolefin laminate.
  • the reservoir can further include an antioxidant.
  • the antioxidant can include propyl gallate.
  • FIG. 1 Cross section view of an occlusive drug delivery device.
  • FIG. 2. In vitro cadaver skin permeation from 0.05% clobetasol propionate adhesive formulations compared to 0.05% ointment.
  • FIG. 3 In vitro cadaver skin permeation from 0.05% clobetasol propionate adhesive formulations compared to 0.05% ointment.
  • FIG. 4 In vitro cadaver skin permeation from 0.05% clobetasol propionate silicone adhesive formulations - effect of trimethyl silyl end capping (4202) versus silanol end capping (4502).
  • FIG. 5 Peel adhesion from HDPE, initial and delayed testing with silicone blend formulations.
  • FIG. 6 Shear creep compliance testing with silicone blend formulations.
  • FIG. 7 Effect of backing film on clobetasol propionate human cadaver skin permeation.
  • FIG. 8 Effect of backing film occlusion on clobetasol propionate human cadaver skin permeation.
  • Clobetasol propionate is a potent corticosteroid used, for example, in topical drug formulations for treating atopic dermatitis, psoriasis, and several other skin conditions.
  • Clobetasol propionate is currently available by prescription in a variety of topical dosage forms, including ointments, lotions, creams, and foams, but is not available in a formulation suitable for delivery via an occlusive delivery device.
  • a formulation of clobetasol propionate designed for delivery via an occlusive delivery device can provide occlusion of the dosing site, which can hydrate the skin. Maintaining skin hydration can increase penetration of drug into the skin. Delivery of clobetasol propionate via an occlusive delivery device also can provide more precise dosing relative to other topical dosage forms, protect the dosing site from itching and scratching, and/or reduce mess during and after application, thereby reducing the likelihood and/or extent to which clobetasol propionate may be undesirably transferred to clothing, skin that is not in the treatment area, other surfaces, or other persons.
  • FIG. 1 illustrates an exemplary embodiment of the drug delivery device 10 in cross- section.
  • the drug delivery device 10 generally includes a substrate 11 that includes a film cured under an atmospheric-pressure nitrogen dielectric barrier discharge.
  • a reservoir 20 is disposed on at least a portion of the substrate 11.
  • the reservoir 20 includes an adhesive composition and clobetasol propionate.
  • a release liner 12 is disposed on at least a portion of the reservoir 20.
  • the substrate 11 can be formed from any suitable material. Suitable materials include materials flexible enough that the substrate 11, and therefore the drug delivery device 10, can conform to the contours of the skin to which the drug delivery device 10 is applied. Suitable materials include conventional flexible backing materials used for pressure sensitive adhesive tapes, including, for example, polyethylene (particularly low density polyethylene, linear low density polyethylene, metallocene polyethylene, or high density polyethylene), polypropylene, polyesters such as polyethylene terephthalate, randomly oriented nylon fibers, ethylene-vinyl acetate copolymer, polyurethane, natural fibers such as rayon, and the like. Suitable materials also include materials that are layered including, but not limited to, polyethylene terephthalate- aluminum-polyethylene composites. The substrate material should be substantially inert to the components of the reservoir 20.
  • the substrate 11 can provide an occlusive backing, which can promote hydration of the skin in the treatment area covered by the drug delivery device 10.
  • a drug delivery device having an occlusive backing is referred to herein as an occlusive drug delivery device.
  • the substrate 11 may be formed from low density polyethylene (LDPE) film, which is a low modulus film relative to other polymer backing materials.
  • LDPE low density polyethylene
  • One exemplary low density polyethylene film is a 1.7 mil LDPE film (COTRAN, 3M Corp., St. Paul, MN).
  • COTRAN 3M Corp., St. Paul, MN
  • Several other lower modulus three-layer composite films were also evaluated and found to provide adequate adhesion to the knee and elbow joints.
  • the exemplary 1.7 mil LDPE substrate film is occlusive, so that the skin hydrates and the clobetasol propionate more easily permeates the skin.
  • Non-occlusive substrate films can reduce delivery to the skin.
  • the substrate is inert to, and resistant to uptake of, clobetasol propionate so that the clobetasol propionate remains available for delivery to the skin from the reservoir 20.
  • the substrate film is cured under an atmospheric-pressure nitrogen dielectric barrier discharge.
  • the process for curing the substrate film in this manner is described in, for example, U.S. Patent No. 7,442,442.
  • Curing the substrate film under an atmospheric-pressure nitrogen dielectric barrier discharge provides an unexpected benefit in product stability. Subjecting the substrate film to air corona-treatment resulted in a cl obetasol -related impurity being formed in the reservoir 20. Untreated substrate films resulted in impurities forming in the reservoir 20 after six months at accelerated conditions, simulating approximately two years of storage at room temperature. In contrast, the substrate film cured under an atmospheric-pressure nitrogen dielectric-barrier discharge did not form impurities in the reservoir 20.
  • the atmospheric-pressure nitrogen dielectric barrier discharge curing treatment used to prepare the films described herein significantly reduces — and in some cases can eliminate — oxygenated species on the film surface that can cause impurities.
  • the effect of curing the film under an atmospheric-pressure nitrogen dielectric barrier discharge therefore provides a cleaner film surface compared to an untreated substrate film.
  • the atmospheric-pressure nitrogen dielectric barrier discharge curing process may crosslink a thin layer of the LDPE creating a greater barrier to migration of low level residual reactive species from the substrate film and into the clobetasol propionate-containing reservoir 20.
  • the reservoir 20 includes clobetasol propionate and an adhesive composition.
  • the clobetasol propionate can be provided at a minimum concentration of at least 0.005 wt% such as, for example, at least 0.010 wt%, at least 0.015 wt%, at least 0.02 wt%, at least 0.025 wt%, at least 0.03 wt%, at least 0.04 wt%, at least 0.05 wt%, at least 0.06 wt%, at least 0.07 wt%, at least 0.08 wt%, at least 0.09 wt%, or at least 0.10 wt%.
  • the clobetasol propionate can be provided at a maximum concentration of no more than 1.0 wt% such as, for example, no more than 0.90 wt%, no more than 0.80 wt%, no more than 0.70 wt%, no more than 0.60 wt%, no more than 0.50 wt%, no more than 0.40 wt%, no more than 0.30 wt%, no more than 0.20 wt%, no more than 0.10 wt%, or no more than 0.05 wt%.
  • the clobetasol propionate can be provided in a concentration expressed as a range having endpoints defined by any minimum concentration listed above and any maximum concentration listed above that is greater than the minimum concentration.
  • the clobetasol propionate can be provided at a concentration of from 0.005 wt% to 1.0 wt% such as, for example, from 0.025 wt% to 0.10 wt%.
  • the clobetasol propionate can be provided in at a concentration equal to any minimum concentration or any maximum concentration.
  • clobetasol propionate can be provided at a concentration of 0.025 wt%, 0.03 wt%, 0.04 wt%, 0.05 wt%, 0.06 wt%, 0.07 wt%, 0.08 wt%, 0.09 wt%, or 0.10 wt%.
  • the adhesive composition can include any polymer, or combination of polymers, that provides a desirable combination of adhesion to the skin and delivery of clobetasol propionate.
  • exemplary suitable polymers include, but are not limited to, acrylates, silicones, polyisobutylenes, and mixtures thereof.
  • the adhesive composition can include a silicone adhesive composition. Many common silicone polymers have silanol end groups that can cause compatibility issues with certain amine containing drugs or excipients.
  • the adhesive composition includes condensation polymers of poly dimethyl siloxane and a silicate resin.
  • the adhesive composition includes one or more “amine compatible” adhesives that have trimethyl silyl end groups rather than silanol end groups. Formulations using adhesives with the trimethyl silyl groups provide superior delivery to and through the skin compared to equivalent formulations utilizing silanol-containing silicones. This observation was unexpected since clobetasol propionate is not an amine-containing compound and was not expected to interact with silanols.
  • the improved delivery using amine compatible adhesives may be a solubility effect - the silanol groups enable a higher solubility of clobetasol propionate within the adhesive matrix, which reduces the thermodynamic activity of the clobetasol propionate in the adhesive composition and lowers the driving force for delivery to and through the skin.
  • acrylate adhesives that have much higher solubility than either variety of silicone adhesive provide reduced delivery of clobetasol propionate into and through skin.
  • Polyisobutylene (PIB) adhesives provided adequate delivery but were not as durable as the silicone adhesives, which may be acceptable for applications in which durability is less of a concern.
  • components of the adhesive composition may be selected to reduce solubility and thereby drive drug delivery.
  • the trimethyl silyl end-capped silicones had the lowest clobetasol propionate solubility (approximately 0.1 wt.%) of any of the tested adhesives.
  • the adhesive composition includes 70/30 blend of two siloxane polymers with trimethyl silyl groups (DC4202 and DC4302, Dow Corning Corp., Midland, MI).
  • the difference between the two adhesives lies in the ratio of silicate resin to polydimethylsiloxane (PDMS) polymer.
  • the DC4302 adhesive contains a 60/40 blend of resin to polymer, while the DC4202 contains a 55/45 blend.
  • a 70/30 blend contains 70 parts 4302 to 30 parts 4202, which results in an overall resin to polymer ratio of approximately 58:42.
  • the adhesive composition can include a blend of DC4202 and DC4302 that ranges from about 40/60 to about 80/20.
  • a 40/60 blend provides a silicate resin to PDMS polymer ratio of 57:43.
  • An 80/20 blend provides a silicate resin to PDMS polymer ratio of 59:41. Compositions within this range balance tack and cold flow properties of the component adhesive blends.
  • the drug delivery device described herein delivers clobetasol propionate to and/or through skin at a slower rate than commercially available lotion and/or ointment formulations. Reducing clobetasol propionate systemic exposure is considered desirable, and the reduced delivery rate from the drug delivery device can result in reduced systemic exposure in vivo compared to lotion and/or ointment formulations.
  • the drug delivery device 10 also includes a release liner 12.
  • the devices can include a release liner that covers and protects the skin-contacting surface, e.g., the adhesive composition, prior to application to a subject.
  • Suitable release liners include, but are not limited to, conventional release liners that include a known sheet material, such as a polyester web, a polyethylene web, a polypropylene web, or a polyethylene-coated paper coated web with a suitable fluoropolymer or silicone-based coating.
  • the devices can be packaged individually (e.g., in a foil-lined pouch) for storage or, alternatively, be provided in a rolled or stacked form suitable for use with a dispensing apparatus.
  • over-formulation of clobetasol propionate may be desirable to compensate for losses of clobetasol propionate during the manufacturing process and/or to the release liner.
  • certain release liner materials may take up as much as 15% of the loaded clobetasol propionate.
  • the reservoir also can include one or more excipients. Certain excipients modulate the solubility of the clobetasol propionate within the formulation, enhance skin penetration of clobetasol propionate, modify adhesive properties, and/or minimize drug degradation.
  • Exemplary excipient materials include C8-C36 fatty acids such as isostearic acid, octanoic acid, and oleic acid; C8-C36 fatty alcohols such as oleyl alcohol and lauryl alcohol; lower alkyl esters of C8- C36 fatty acids such as ethyl oleate, isopropyl myristate, butyl stearate, and methyl laurate; di(lower) alkyl esters of C6-C8 diacids such as diisopropyl adipate; monoglycerides of C8-C36 fatty acids such as glyceryl monolaurate; tetraglycol (tetrahydrofurfuryl alcohol polyethylene glycol ether); tetraethylene glycol (ethanol, 2, 2'-(oxybis(ethylenoxy))diglycol); C6-C36 alkyl pyrrolidone carboxylates; polyethylene glycol; propylene
  • Alkylaryl ethers of polyethylene oxide, polyethylene oxide monomethyl ethers, and polyethylene oxide dimethyl ethers are also suitable, as are solubilizers such as glycerol, triacetin, N-methyl pyrrolidone.
  • Terpenes are another useful class of softeners, including pinene, d-limonene, carene, terpineol, terpinen-4-ol, carved, carvone, pulegone, piperitone, menthone, menthol, neomenthol, thymol, camphor, homed, citral, ionone, and cineole, alone or in any combination.
  • excipients enumerated above are known to affect skin penetration rate, certain excipients affect aspects of performance other than and/or in addition to skin penetration rate. For example, certain excipients may be useful in softening or increasing the compliance value and/or lowering the glass transition temperature of polymers, such that the resulting composition is more suitable for use as a pressure sensitive adhesive.
  • the excipient or excipients can be dispersed, preferably substantially uniformly, and more preferably dissolved in the composition.
  • the excipient is a penetration enhancer
  • it can be present in an amount that enhances drug permeation through the skin compared to a like composition that does not contain the penetration enhancer when this phenomenon is measured using a standard skin penetration model, such as in U.S. Pat. No. 5,585,111, the disclosure of which is herein incorporated by reference.
  • the total amount of excipient will generally be about 0.1% to about 40% by weight based on the total weight of the composition.
  • the reservoir can include an antioxidant as an excipient.
  • antioxidants include, but are not limited to, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), tertiary butyl hydroquinone (TBHQ), propyl gallate, ascorbic acid and esters thereof (e.g., ascorbyl palmitate), tocopherol and esters thereof (e.g., tocopherol acetate and including isomers thereof), polyphenolic antioxidants, flavinoids, isoflavinoids, neoflavinoids, quercetin, rutin, epicatechins, resveratrol, thioglycerol, thioglycolic acid, thiourea, acetylcysteine, sodium bisulfite, sodium sulfite, sodium metabi sulfite, cyclodextrins (to cover site of active pharmaceutical compound subjected to oxidation), and carotenoids.
  • BHA butylated hydroxyanisole
  • BHT
  • the drug delivery device 10 may be prepared by combining the clobetasol propionate, the selected components of the adhesive composition, and any additional excipients with an organic solvent (e.g., ethyl acetate, isopropanol, methanol, acetone, 2-butanone, ethanol, toluene, alkanes, or a mixture thereof) to provide a coating composition.
  • an organic solvent e.g., ethyl acetate, isopropanol, methanol, acetone, 2-butanone, ethanol, toluene, alkanes, or a mixture thereof
  • the mixture is shaken or stirred until a homogeneous coating composition is obtained.
  • the resulting composition is then applied to a release liner using conventional coating methods (e.g., knife coating or extrusion die coating) to provide a predetermined uniform thickness of coating composition.
  • the drug delivery device can be in the form of an article such as a tape, a patch, a sheet, a dressing, or any other form known to those skilled in the art.
  • the device will be in the form of a patch of a size suitable to deliver a preselected amount of clobetasol propionate through the skin.
  • the device will have a surface area of about 5 cm 2 to about 500 cm 2 .
  • it may be useful to use multiple patches to provide the most effective treatment to patients with multiple sites or larger surface areas affected by atopic dermatitis or psoriatic lesions.
  • the device may take the form of a patch having a plurality of sections separated by perforations.
  • the described formulation can be used in the context of any delivery device having a backing material for handling and/or occlusion purposes.
  • the clobetasol propionate formulation is referred to herein as a “patch” formulation
  • the formulation may be used in the context of, for example, a bandage, a wrap, a plaster, a dressing, etc.
  • FIG. 2 shows better absorption from silicone (BIO-PSA 7-4302) relative to a selection of acrylates and acrylate/ silicone blends.
  • DC4202 trimethyl silyl-end-capped siloxane polymer
  • DC4502 silanol groups
  • Blends of the “high tack” DC4302 and “medium tack” DC4202 adhesives were evaluated for in vitro adhesion to high density polyethylene (HDPE) test plates (FIG. 5) and for their compliance (FIG. 6).
  • HDPE high density polyethylene
  • FIG. 6 Comparisons of the “high tack” DC4302 and “medium tack” DC4202 adhesives were evaluated for in vitro adhesion to high density polyethylene (HDPE) test plates (FIG. 5) and for their compliance (FIG. 6)).
  • the adhesive performance is quite sensitive to these changes, with large swings in the both the peel adhesion and the compliance values.
  • Adhesives richer in 4302 had higher compliance and better initial adhesion.
  • Adhesives with more 4202 had lower compliance and higher adhesion after 30 minutes of dwell time.
  • a 70/30 blend of 4302/4202 provides a shear creep compliance value of approximately 2 c 10 5 cm 2 /dyne, which is line with the compliance value of other transdermal delivery adhesive formulations designed for 24-hour wear.
  • a clinical adhesion panel confirmed the acceptability of both 70/30 and 50/50 blends in adhesion to sites on the knee and elbow.
  • the term “and/or” means one or all of the listed elements or a combination of any two or more of the listed elements; the terms “comprises,” “comprising,” and variations thereof are to be construed as open ended — i.e., additional elements or steps are optional and may or may not be present; unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one; and the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
  • the steps may be conducted in any feasible order. And, as appropriate, any combination of two or more steps may be conducted simultaneously.
  • Clobetasol propionate and solvated adhesive polymer composition are weighed and added in the desired proportions to an appropriately sized vessel.
  • the clobetasol propionate may be pre-dissolved in ethyl acetate, NF at approximately 5-8 wt.% before adding to the adhesive.
  • Any excipients are added to the vessel in the desired proportion, and the contents of the vessel are mixed until a uniform solution is obtained.
  • the drug-in-adhesive solution is then coated on a release liner at the desired dry coating weight (e.g., 5 mg/cm 2 ) using a suitable coating method (such as a knife coater) to obtain a uniform coating on the liner.
  • a suitable coating method such as a knife coater
  • the coated liner is then placed in an oven for a period of time (e.g., a Despatch convection oven at 43°C for 10 minutes) to remove the solvent and obtain a dried drug-in-adhesive coating on the release liner.
  • the coated liner is then laminated to the desired backing film by bringing them together through a nip where pressure is applied to adhere the drug-in-adhesive coating to the backing (such as with a Laminex laminator).
  • the liner was Scotchpak 9744 (3M Co., St. Paul, MN) and the backing was CoTran 9719 (3M Co., St. Paul, MN) unless stated otherwise.
  • a punch, steel-rule die or other suitable tooling is then used to punch through the laminated material and create patches of the desired size.
  • Backing films were treated with a corona discharge using a corona treatment process as disclosed in U.S. Patent No. 7,442,442, the disclosure of which is incorporated by reference herein.
  • nitrogen treatment the internal atmosphere within the corona treater was filled with nitrogen gas — i.e., a maximum of 100 ppm oxygen.
  • the backing film is conveyed through the corona treater and is exposed to the corona discharge.
  • a range of energy levels may be used (for example, 0.1 - 2.5 Joules/cm 2 ), but the most preferable level for treatment of CoTran 9719 backing film is approximately 0.5 Joules/cm 2 .
  • the backing film may be treated on both sides by running the film through the corona treater a second time, or by using a dual electrode corona treater.
  • Each study used dermatomed partial thickness human cadaver skin (full epidermis, partial dermis), which was cryopreserved and stored at -60°C until prepared for the study.
  • the frozen skin was prepared for use by thawing and equilibrating in an antimicrobial solution on the day prior to the study (total preparation time is typically between 16-24 hours). After preparation, the skin was carefully and thoroughly patted dry and cut into appropriately sized sections for the respective sample/cell size. Any damaged skin was screened out prior to use. Skin samples are randomly selected during sample application.
  • the studies used static modified Franz diffusion cells. The cells used have a 5 mL receptor solution volume for tape samples or a 25 mL volume for the ointment.
  • the receptor solution was continually circulated via a stir bar.
  • the environmental chamber that contains the Franz cells was maintained at 32°C.
  • the receptor solution was a pH 7.4 phosphate buffered saline solution with 20% (v/v) PEG-400 and an antimicrobial.
  • Patch samples were 1 cm 2 and the target coating weight was 5 mg/cm 2 unless noted otherwise.
  • the ointment was applied over a ⁇ 1 cm 2 area with a target dose of between 4-6 mg to match the tape samples.
  • the study run time was 24 hours with a single pull point at the end of the study.
  • the receptor solution was sampled at the end of the study. Approximately 1.5 ml of the receptor solution was filtered through a 0.45-micron filter, placed in an HPLC vial and capped. HPLC vials were refrigerated until analysis by HPLC. Patches were carefully removed from the skin after study completion and placed in a vial for extraction followed by analysis by HPLC. Any residual adhesive after removal was gently rolled off and added to the sample vial. Residual ointment was wiped from the skin using one cleaning swab soaked in ethanol followed by one dry swab. The swabs were placed in vials for extraction followed by HPLC analysis. The skin samples were placed in a vial for extraction followed by HPLC analysis. The assayed values were used to calculate the amount and the percentage of the applied dose found in each compartment (patch or ointment, skin, and receptor).
  • Patch samples containing 0.05 wt.% clobetasol propionate were prepared according to the method above with a selection of different adhesive polymers. The samples were coated at a target coating weight of 10 mg/cm 2 and the backing film was CoTran 9720 (3M Co., St. Paul, MN). In vitro human cadaver skin permeation results with each adhesive polymer along with a 0.05 wt.% ointment control is shown in Table 1 and FIG. 2.
  • Patch samples containing 0.05 wt.% clobetasol propionate were prepared according to the method above with two different adhesive polymers.
  • In vitro human cadaver skin permeation results with each adhesive polymer along with a 0.05 wt.% ointment control is shown in Table 2 and FIG. 3.
  • Patch samples containing 0.05 wt.% clobetasol propionate were prepared according to the method above with two different silicone adhesive polymers, one with silanol end groups (BIO- PSA 4502 and one with trimethyl silyl end groups (BIO-PSA 4202).
  • BIO- PSA 4502 silanol end groups
  • BIO-PSA 4202 trimethyl silyl end groups
  • Table 3 and FIG. 4 In vitro human cadaver skin permeation results with each adhesive polymer along with a 0.05 wt.% ointment control is shown in Table 3 and FIG. 4.
  • Patch samples containing 0.05 wt.% clobetasol propionate were prepared according to the method above with binary silicone adhesive mixtures of BIO-PSA 7-4302 (medium tack) and BIO-PSA 7-4202 (low tack) polymers.
  • the 180-degree peel strength to high density polyethylene test plates was measured using a Texture Analyzer tensile tester approximately one minute after application to the plate and 30 minutes after application to the plate. The average peel strength was obtained from a minimum of six replicate samples.
  • the shear creep compliance was measured using a custom tester designed to measure the displacement of two 5 cm 2 patches when placed under a 500 g shear force. The results are shown in Table 4, FIG. 5, and FIG. 6.
  • Table 4 Average adhesive 180-degree peel strength to high density polyethylene
  • Example 5 Patch samples containing 0.05 wt.% clobetasol propionate were prepared according to the method above with BIO-PSA 7-4302 adhesive polymer. This single formulation was coated, dried, and laminated to a range of different backing materials. The in vitro permeation results are shown in Table 5 and FIG. 7.
  • Patch samples containing 0.05 wt.% clobetasol propionate were prepared according to the method above with a 70:30 blend of BIO-PSA 7-4302 and BIO-PSA 7-4202 adhesive polymers. This single formulation was coated, dried, and laminated to three different lots of CoTran 9719 backing, each with a different surface treatment. One of the backings was untreated, another was corona treated in ambient air, and the third was corona treated in a nitrogen atmosphere. Samples were packaged in a foil pouch and stored at 40°C/75%RH. The impurity profile was monitored over time via an HPLC method. The results are shown in Table 6.
  • Example 7 Patch samples containing 0.05 wt.% clobetasol propionate and 0.5 wt.% of an antioxidant in a 70:30 blend of BIO-PSA 7-4302 and BIO-PSA 7-4202 adhesive polymers were prepared by the general method described above. Samples were packaged in a foil pouch and stored at 40°C/75%RH. The generation of clobetasone propionate (an oxidative degradant of clobetasol propionate) was monitored over time via an HPLC method. The results are shown in Table 7.
  • Patch samples containing 0.05 wt.% clobetasol propionate in a 70:30 blend of BIO-PSA 7-4302 and BIO-PSA 7-4202 adhesive polymers were prepared by coating on each of five different release liners. The coatings were dried at 150°F for 10 minutes, then laminated to Scotchpak 9744 (3M Co., St. Paul, MN) release liner. The three layers of the resulting laminate (coating liner, adhesive matrix, and cover liner) were assayed individually for clobetasol propionate content via HPLC within hours of the coating process. The results of the content analysis are shown in Table 8.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Dispositif d'administration de médicament comprenant généralement un substrat qui comporte un film durci par une décharge à barrière diélectrique à l'azote sous pression atmosphérique, un réservoir disposé sur au moins une partie du substrat, et une pellicule de protection disposée sur au moins une partie du réservoir. Le réservoir comprend généralement une composition adhésive et du propionate de clobétasol.
PCT/US2021/040467 2020-07-06 2021-07-06 Dispositif d'administration de médicament pour l'administration de propionate de clobétasol WO2022010864A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063048516P 2020-07-06 2020-07-06
US63/048,516 2020-07-06

Publications (1)

Publication Number Publication Date
WO2022010864A1 true WO2022010864A1 (fr) 2022-01-13

Family

ID=77168432

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/040467 WO2022010864A1 (fr) 2020-07-06 2021-07-06 Dispositif d'administration de médicament pour l'administration de propionate de clobétasol

Country Status (1)

Country Link
WO (1) WO2022010864A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585111A (en) 1993-12-08 1996-12-17 Minnesota Mining And Manufacturing Company Transdermal delivery device
US7442442B2 (en) 2004-07-01 2008-10-28 3M Innovative Properties Company Methods, systems, and polymer substances relating to consideration of H2O levels present within an atmospheric-pressure nitrogen dielectric-barrier discharge
US20120321673A1 (en) * 2011-06-20 2012-12-20 Takahiro Ogawa Transdermal drug delivery system and method of using the same
WO2015006531A1 (fr) * 2013-07-11 2015-01-15 Momentive Performance Materials Inc. Composition de silicone à deux modalités de durcissement

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585111A (en) 1993-12-08 1996-12-17 Minnesota Mining And Manufacturing Company Transdermal delivery device
US7442442B2 (en) 2004-07-01 2008-10-28 3M Innovative Properties Company Methods, systems, and polymer substances relating to consideration of H2O levels present within an atmospheric-pressure nitrogen dielectric-barrier discharge
US20120321673A1 (en) * 2011-06-20 2012-12-20 Takahiro Ogawa Transdermal drug delivery system and method of using the same
WO2015006531A1 (fr) * 2013-07-11 2015-01-15 Momentive Performance Materials Inc. Composition de silicone à deux modalités de durcissement

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DANIL DOBRYNIN ET AL: "Paper;Inactivation of bacteria using dc corona discharge: role of ions and humidity;Inactivation of bacteria using dc corona discharge: role of ions and humidity", NEW JOURNAL OF PHYSICS, INSTITUTE OF PHYSICS PUBLISHING, BRISTOL, GB, vol. 13, no. 10, 24 October 2011 (2011-10-24), pages 103033, XP020212196, ISSN: 1367-2630, DOI: 10.1088/1367-2630/13/10/103033 *

Similar Documents

Publication Publication Date Title
US6139867A (en) Medical adhesive sheet
US7888422B2 (en) Long-wearing removable pressure sensitive adhesive
US7247315B2 (en) Compositions and medical device for transdermal delivery of a drug and methods of making and using same
EP0711551B1 (fr) Préparation pour absorption percutanée
BRPI0808864A2 (pt) Dispositivo de dispensação transdérmica, e, métodos para preparar uma matriz adesiva, para remover núcleos de cristalização e reestabelecer o ambiente de matriz adesiva interna favorecido de um dispositivo de dispensação de medicamento transdérmica e para armazenar e proteger um dispositivo de dispensação transedérmica.
CZ307857B6 (cs) Transdermální náplast pro podávání fentanylu nebo jeho analogu
IE873541L (en) Transdermal estrogen/progestin dosage unit
KR101215247B1 (ko) 점착 부재 및 첩부제
JP2007509951A (ja) 経皮的なドラッグデリバリーシステムにおける医薬品の損失及び送達を制御するための組成物及び方法
EP0917461A1 (fr) Dispositif pour le traitement local de l'acne et procede de fabrication associe
AU2002329763A1 (en) Composition and transdermal drug delivery device
EP0531938B1 (fr) Gel acrylique, et préparation le contenant pour l'absorption percutanée
US10307380B1 (en) Composition and method for transdermal lidocaine delivery
BRPI0621577A2 (pt) sistema terapêutico transdermal para substáncias voláteis e/ou termolábeis
WO2022010864A1 (fr) Dispositif d'administration de médicament pour l'administration de propionate de clobétasol
AU3340997A (en) Device for topical treatment of acne and its method of manufacture
KR20060123551A (ko) 최소한 한 개의 지방산을 포함하는 디하이드로피리딘 타입칼슘 길항제용 경피 전달 장치
US20170340580A1 (en) Bioadhesive patch
JP2020532582A (ja) リバスチグミンの経皮投与のための経皮治療システム
JPS61221120A (ja) 外用医薬部材
US20230058378A1 (en) Anti-itch scar management products, process of manufacture and useful articles thereof
KR20240079179A (ko) 칸나비디올을 유효성분으로 포함하는 경피흡수 패치제
WO2019126166A1 (fr) Compositions pharmaceutiques transdermiques à irritation cutanée réduite
CN101304735A (zh) 用于挥发性和/或热不稳定的物质的经皮治疗体系
EP2238990A2 (fr) Patch et préparation de patch

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21749434

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 21749434

Country of ref document: EP

Kind code of ref document: A1